u/DermSherpa

RDW stands for red cell distribution width, and it measures how much your red blood cells vary in size. It appears on every standard CBC, but historically it was used narrowly, mostly as a clue when working up anemia, since conditions like iron deficiency make cell sizes more uneven. For decades it was a supporting character. What has become clear is that RDW behaves like a general distress signal. Across large population studies, higher RDW is independently associated with all-cause mortality, cardiovascular disease, heart failure, and cancer, and the association holds even in people who are not anemic and after adjusting for the usual risk factors. The leading explanation is that uneven red cell size reflects background inflammation, oxidative stress, and disturbed red cell production and turnover, so it ends up being a cheap proxy for "something systemic is off," even when no single diagnosis is obvious.

The recent development is an attempt to sharpen a blunt marker by pairing it with another routine value. Albumin, the main protein on a standard metabolic panel, tends to fall with inflammation and frailty, so combining the two into the RDW-to-albumin ratio (RAR) stacks two different distress signals into one number. Two 2026 NHANES analyses are worth knowing. One mapped out what RAR actually looks like in healthy US adults, using more than 22,000 people weighted to represent about 141 million, and found a fairly tight normal range (a median around 3.0 and most healthy people falling roughly between 2.5 and 4.1), with surprisingly little variation across age, sex, and race. The other looked at adults with low muscle mass and found a clean dose-response: those in the highest RAR quartile had roughly 150% higher all-cause mortality and over 200% higher cardiovascular mortality than the lowest, and RAR edged out several popular inflammatory ratios at most time points.

The honest limits matter, because this is the kind of finding that gets oversold. RDW is nonspecific, and it rises for mundane reasons: iron, B12, or folate deficiency, recent blood transfusion, or liver disease, none of which are exotic. It is a marker, not a cause, so no one is suggesting you can lower your mortality by lowering RDW directly. On its own it is a modest predictor, with discrimination in other studies landing in the low-to-mid range rather than anything decisive, and the mortality-gradient study above was retrospective and in a specific subgroup. So this is a useful flag layered on top of clinical judgment, not a standalone verdict.

What you can follow

The open question is whether RDW and RAR add real predictive value once you already know someone's standard risk factors in a general population, versus just re-flagging people who are visibly unwell. The biology is genuinely interesting too, since it is not obvious why variability in red cell size should forecast death from causes that have nothing to do with blood. Worth watching, and worth a little skepticism: there is now a small industry of composite CBC ratios (RDW-to-albumin, hemoglobin-to-RDW, neutrophil-to-lymphocyte, and more), and some of that is real signal while some is likely overfitting to specific datasets. The ones that survive across many independent cohorts are the ones to trust.

Are there tests available today to measure this?

This is the easiest yes in the whole series, because you almost certainly already have the data. RDW is on every CBC, and albumin is on every basic metabolic panel, so if you have any recent routine bloodwork you can read your RDW directly and compute RAR yourself by dividing RDW by albumin. The main caveat is that RDW values vary a little between lab analyzers, so compare against your own lab's reference range rather than a number from a study, and treat the roughly 2.5 to 4.1 RAR window as a general guide, not a hard cutoff. And before reading anything ominous into a high value, the boring causes (iron, B12, folate) should be ruled out first. If people here have pulled their own RDW trends from past labs, it would be interesting to compare how stable the number is over years.

What you can track

Because you likely have several past CBCs, this is one you can track retrospectively as well as going forward. Pull your RDW from old and new bloodwork and look at the trend rather than a single reading. A value drifting upward over time, or sitting at the high end, is a reasonable prompt to check for treatable contributors with a clinician (nutrient deficiencies and sources of chronic inflammation), not a reason to panic. The modifiable inputs underneath it are the familiar ones: correcting iron or B vitamin deficiencies if present, and the general anti-inflammatory levers of fitness, body composition, and not smoking. As always with a nonspecific marker, context and trend beat any one number.

Papers: https://doi.org/10.1155/bmri/9956220 and https://doi.org/10.1177/03000605251413087

Two quick definitions, because the whole point here is measurability. The Omega-3 Index is the percentage of EPA and DHA in your red blood cell membranes, and unlike a one-off blood draw it reflects your average intake over the past few months, so it is hard to game and good for tracking. The neutrophil-to-lymphocyte ratio, or NLR, is just the count of one white blood cell type divided by another, a cheap and general readout of immune balance and low-grade inflammation. When chronically elevated, higher NLR has been linked in observational studies to greater risk of cardiovascular events like heart attack and stroke, worse survival across a range of cancers, type 2 diabetes and its complications, and higher all-cause mortality, though it travels as a marker of underlying trouble rather than a proven cause of it.

The authors pooled individual-level data from four supplementation studies (three placebo-controlled trials plus one supplement-then-washout study), combining 436 healthy adults, and asked a simple question: does taking EPA and DHA move these markers. At an average dose of about 1,160 mg per day, omega-3 raised the Omega-3 Index substantially, while it drifted down in the control group, which is the expected dose-response and confirms people were actually absorbing it. The NLR dropped in the omega-3 group and barely moved in controls, a statistically significant difference. Red cell distribution width, another CBC-derived marker they checked, did not budge with omega-3. And the change in Omega-3 Index was inversely correlated with the change in NLR, meaning the more someone's index rose, the more their NLR tended to fall.

The honest limits, which matter here. The NLR effect was small in absolute terms, and the correlation between the index change and the NLR change was weak even though it reached significance. This was in healthy adults, so there was not much inflammation to fix in the first place, and the authors are explicit that dedicated trials are needed to know whether a shift this size means anything clinically. One conflict worth naming: several authors are affiliated with the Fatty Acid Research Institute, and the Omega-3 Index is a commercialized test co-developed by one of them, so read the enthusiasm for the index accordingly.

What you can follow

Zoom out and the omega-3 story is genuinely unsettled at the level that matters, hard outcomes. Large cardiovascular trials have disagreed, with results swinging on dose, formulation (prescription EPA versus mixed EPA/DHA), and the placebo oil used. So the live question is whether nudging a marker like NLR downward translates into fewer events, or whether NLR is just a thermometer that omega-3 happens to cool slightly. The dose-response on the index is the more solid part, and it is worth watching how much EPA/DHA it actually takes to push most people into the commonly cited target range.

Are there tests available today to measure this?

Yes, and this is about as trackable as it gets with real labs. The NLR is essentially free: it is calculated from a complete blood count with differential, which you very likely already have on past bloodwork, just divide the neutrophils by the lymphocytes. RDW comes off that same CBC. The Omega-3 Index is a specific finger-prick test you can order directly from a few labs for a modest fee, and it is the readout that tells you whether your supplement is doing anything at the membrane level. The big caveat on NLR is that it is nonspecific and jumps around with any infection, recent hard workout, or acute stress, so a single value means little. If anyone here tracks their Omega-3 Index or NLR over time, real numbers on how much a given dose moved your index would be useful, since individual absorption varies a lot.

What you can track

This one closes the loop with two labs. First, the intervention check: if you start EPA and DHA, retest the Omega-3 Index at around 12 weeks to confirm you actually moved it, since dose and absorption vary and plenty of people take fish oil without shifting their index much. Second, the downstream marker: pull your NLR from routine CBCs over time. Because NLR is noisy and nonspecific, only compare readings taken when you are well and look at the trend across several draws rather than reacting to one. Treat it as a personal experiment, not a guarantee, given how small the average effect was.

Paper: https://doi.org/10.1016/j.tjnut.2026.101663

Alpha waves are one of the few things you can watch the living brain do in real time. Put electrodes on the scalp, have someone close their eyes and relax, and a slow rhythm in the 8 to 14 Hz range rises up across the back of the head. It fades the moment they engage with something. Because that rhythm tracks a calm, alert, internally focused state, it became the headline biomarker for nootropics that promise "calm focus," L-theanine above all. So the tempting question is the same one that haunts every biomarker: if a compound moves the wave, is it actually changing how your mind works, or just changing a readout that happens to be easy to measure.

This Foxe-lab study went at that question more honestly than most. Earlier work had shown L-theanine bumps alpha while people rest with their eyes closed, which tells you it changes brain state but not that it helps you do anything. So here they put it inside a real task. They recorded 168-channel EEG from thirteen people during a demanding visuo-spatial attention task, where a cue told you to shift attention left or right before a target appeared, and tested 250 mg of tasteless L-theanine against a water placebo on two separate days, counterbalanced. The key move was splitting alpha into two kinds. Tonic alpha is the slow background level, a brain-state measure. Phasic alpha is the quick, cue-triggered dip and rise that actually gates attention toward the relevant side and away from the irrelevant one. Marketing collapses both into the word "focus," but they are different mechanisms, and the study tested each on its own. L-theanine produced a real, significant drop in tonic alpha and shifted where that activity sat on the scalp. But it did not measurably move the phasic, cue-locked alpha that does the actual work of selecting what you attend to. Their read was that L-theanine supports the longer-lasting processes that sustain attention across a hard task, rather than the moment-to-moment deployment.

Now the caveats, because this gets oversold fast. The phasic effect is the more cognitively interesting one, and this is the same lab that had previously found it present in a different task, so this was a partial failure to replicate the better story, not a clean win. It is also a small proof-of-mechanism paper: thirteen people, a single 250 mg dose with no dose-response, one session per condition, and EEG endpoints rather than a headline behavioral performance gain. What it shows is how L-theanine acts on the attention system, not that you will measurably think better. That is mechanistic evidence, and it sits below RCTs with behavioral outcomes in the hierarchy.

What you can follow
The real question with any "it changes your brain waves" claim is whether the wave change buys you anything once you account for the obvious. A shift in tonic alpha is a state change. The interesting claim is that the state change improves performance, and that link is exactly what this paper does not establish. Also worth watching across this literature: the effect is clearer in higher-anxiety people and at doses far above a cup of tea, and replications do not all reach significance. When you see "boosts alpha for focus," the questions to ask are which alpha, in what state, at what dose, and did any behavior actually move alongside it.

Are there tests available today to measure this?
Sort of, with a big asterisk. Consumer EEG headbands will happily show you your alpha and even label it "calm," and a research lab can measure your alpha response to a dose cleanly. What does not exist is a validated readout that tells you whether L-theanine is "working" for your attention, because the meaningful endpoint here was a task mechanism, not a single resting number. A rising alpha bar on a wearable is not evidence the compound is improving your cognition. If you have seen an app or device claim to measure your "theanine response" or "focus waves," drop it below, because that is a marketing leap past what these studies support.

What you can track
The honest, version: the thing worth tracking is whether the compound does anything you can actually notice or measure in your real tasks, not whether a wave moved. If you use L-theanine, the testable claims are behavioral, reaction time, error rate, sustained attention on something boring, ideally with and without caffeine since the combination has more behavioral support than theanine alone. Treat the alpha story as a plausible mechanism for why it might feel like calm alertness, and treat any single brain-wave number as a nudge to check whether your actual performance changed, not as proof that it did.

Paper: https://doi.org/10.1007/s10548-008-0068-z

https://preview.redd.it/6qs85b0cz0ah1.png?width=480&format=png&auto=webp&s=f3eb49270fa4387a41574ae11e1dc07798c06ebe

The retina is the only place a doctor can look straight at your blood vessels and nerve tissue without a needle or a scalpel. Snap a photo, and you are seeing live human neurovascular tissue. So it has always been a tempting place to ask a bigger question: does the eye tell you something about how the whole body is aging, not just whether you need glasses.

This Stanford group trained deep-learning models on two images you can get at a normal eye appointment. One is the fundus photo, the picture of the back of the eye. The other is OCT, the scan that slices through the retina and shows its layers. Instead of just guessing your age, the models were built to estimate a biological age, and the authors checked that number against the Charlson Comorbidity Index, which is basically a weighted tally of serious diagnoses and a known predictor of dying sooner. A few things came out of it. Using both images together beat using either one. Training on diseased eyes, not just clean healthy ones, made the models better rather than worse, so the disease itself was carrying usable signal. And the predicted biological age tracked a person's disease burden more tightly than their actual age did. They also pulled heatmaps to see where the model was looking.

Now the caveats, because this gets hyped fast. It is a fairly small, proof-of-concept paper. They validated against a comorbidity score, not against who actually got sick or died over the following years, and it is a single snapshot in time. The general idea has stronger evidence behind it, since bigger cohort studies have already tied a fundus-based "retinal age gap" to future death and heart disease. But this particular multimodal version is early work, not something ready for the clinic.

What you can follow

The real question with any of these is whether the eye adds anything once you already know someone's blood pressure and blood sugar, or whether it is just re-reading the same vascular damage in a prettier format. Also worth watching: do these models survive a change of camera or OCT machine. Imaging AI has a bad habit of learning the scanner instead of the patient, and retinal clocks have not really proven they generalize across devices and populations yet. And if you care about mechanism, the heatmaps matter, because "the vessels look old" and "the nerve fiber layer is thinning" are two very different stories about what is going wrong.

Are there tests available today to measure this?

The pictures, yes. Fundus photos are standard, and OCT is increasingly routine at optometrists, sometimes as a cheap add-on, so a lot of people already have these scans sitting in a file somewhere. What you cannot get is the biological-age number, because the algorithm is a research model your eye doctor does not run. A handful of groups and startups are working on retinal-age readouts, but nothing is a validated, off-the-shelf clinical product right now. If you have run into a clinic or app claiming to give you a "retinal age," drop it below. And a quick distinction worth making: an OCT ordered to check your eyes is not the same thing as a tested measure of how your whole body is aging.

What you can track

The blood vessels in your retina are just your body's small vessels in a spot you can photograph, so the things that age them are the usual cardiometabolic suspects: blood pressure, glucose and HbA1c, ApoB, and smoking. Those are all measurable now and they are where the action actually is. The simpler takeaway is unglamorous: get your eyes checked on schedule, since a regular exam catches diabetic and hypertensive damage in the retina well before you would ever notice it. If retinal-age tools do show up, read a single score as a nudge to go look at those underlying numbers, not as a sentence.

Paper: https://doi.org/10.1038/s41598-026-36518-x

Sudden cardiac death is, in principle, preventable with an implantable defibrillator, but the hard part is knowing who needs one. The single biomarker in wide use is left ventricular ejection fraction (LVEF), basically how strongly the heart squeezes, measured by ultrasound. The problem is that LVEF misses most people who die suddenly, and at the same time over-flags others, since about two-thirds of defibrillators placed for low LVEF never end up delivering a life-saving shock. So the field has wanted a better predictor for a long time, and the ECG, which is cheap and everywhere, has been an obvious place to look.

The team trained a deep-learning model on every ECG from an entire Swedish region linked to death certificates, and they did something unusually disciplined: they locked away 40% of the data and did not touch it until after the paper was provisionally accepted, which is about the strongest guard against overfitting you can ask for. In that held-out set the model predicted sudden cardiac death within a year with an AUC of 0.872, well above standard cardiovascular risk scores (around 0.70). Their chosen high-risk group was the riskiest 2.2% of people, who had a 7.0% annual rate of sudden cardiac death, higher than the 4.6% rate in the group with reduced LVEF. The striking number is the overlap: 86% of the model's high-risk patients were not flagged by LVEF at all. Even among people with a normal LVEF, where today there is essentially no way to stratify risk, the model picked out a group at higher risk than the reduced-LVEF patients. And as suggestive (not definitive) evidence of real stakes, high-risk patients who happened to have a defibrillator already in place died about 54% less often than expected.

It held up outside Sweden too. With no retraining, the model hit an AUC of 0.822 for predicting the ventricular arrhythmias that cause sudden death in a US health system, and 0.767 for future arrhythmic cardiac arrests in a Taiwanese registry. They also ran a clever specificity check: the model did poorly (near chance, 0.58) at predicting non-arrhythmic arrests, which is what you want, since it suggests it is picking up arrhythmic death specifically rather than just "sick person." Then the genuinely novel part. Because a neural net cannot tell you what it sees, they paired it with a generative model that morphs a real low-risk ECG into a higher-risk version, letting them visualize the signal. Out came some known features (left axis deviation, poor R-wave progression) plus a previously undescribed one: a slurred tail on the QRS complex in lead aVL. Tracing that back to physiology, they propose diffuse myocardial fibrosis as the underlying culprit, supported by blinded heart-MRI review showing more diffuse scarring in high-risk patients. A telling detail: in those same patients' charts, no cardiologist had ever noted the fibrosis.

The limits are real and the authors are upfront about them. The defibrillator survival benefit is observational, drawn from patients already selected for devices under current practice, so it cannot prove a defibrillator would help these newly flagged patients. They explicitly call for a randomized trial, which is the right next step. The training label, death certificates, is imperfect for pinning down arrhythmic cause, though the multi-country arrhythmia validation cushions that. And this is a research model, not a deployed or cleared tool.

What you can follow

The conceptual shift worth tracking is from structural risk (how weak is the pump) to electrical risk read straight off the waveform, since these turn out to identify largely different people. The thing that would change practice is a randomized trial in the model's high-risk group, so watch for that. Two other threads are interesting: the generative "morphing" approach is a general recipe for turning an opaque model into a human-inspectable hypothesis, and the fibrosis story plus the aVL feature could feed back into ordinary ECG reading if they replicate. AI-ECG is a fast-moving area generally, so expect a wave of similar models, and apply the usual scrutiny about held-out validation and external cohorts.

Are there tests available today to measure this?

The input is about as available as medicine gets: a standard 12-lead ECG is cheap, fast, and probably already in your chart if you have seen a cardiologist. The catch is that this specific model is not a product you can request, not regulatory-cleared, and not running in clinics. Some AI-ECG tools are FDA-cleared for other tasks (detecting low ejection fraction or atrial fibrillation), but not this sudden-death biomarker. One nuance from the paper: single-lead versions of the model performed almost as well on discrimination, which is intriguing for the wearable era, but it would be a real stretch to read this as "your smartwatch can predict sudden cardiac death," and nobody should treat a consumer single-lead trace that way. If anyone here works in a system piloting AI-ECG risk tools, real deployment experience would be valuable, since this field is moving from papers to products quickly.

What you can track

This is a topic where the honest answer is that the action item is professional, not self-tracking. The modifiable, measurable drivers of cardiac risk are the familiar ones (blood pressure, ApoB or LDL, glucose, not smoking, cardiorespiratory fitness), and they are worth tracking on their own merits. But the specific signal here is not something to chase at home. The genuinely useful move is recognizing red flags that warrant a real cardiology workup: unexplained fainting, episodes of racing or irregular heartbeat, or a family history of sudden or unexplained death at a young age. Those are reasons to get evaluated, ECG included, rather than anything to monitor with a gadget.

Paper: https://doi.org/10.1038/s41586-026-10674-6

Early-onset cancer, the kind diagnosed before about 50 to 55, has been rising in younger generations for reasons that are not fully explained by the usual suspects. This study asked whether "biological age," the gap between how old your body looks on molecular and clinical measures versus your actual birthday, is part of the story. The appeal of that framing is that a single age-gap number rolls up the cumulative damage from many exposures at once, which is useful when no single risk factor explains the trend.

The team measured systemic biological age in 154,169 UK Biobank participants who were under 55 at enrollment, using PhenoAge (a clock built from nine routine blood values plus age), and cross-checked with two other clocks (the Klemera-Doubal clinical clock and a metabolomic clock from NMR data). Two things stood out. First, the age gap has drifted older across birth cohorts: people born 1965 to 1974 carried a meaningfully larger PhenoAge gap than those born 1950 to 1954, and in the US All of Us cohort the generational jump looked even steeper. Second, a larger age gap tracked with more early-onset cancer. Each standard-deviation increase in the PhenoAge gap was linked to roughly 8% higher risk of early-onset solid cancer overall, concentrated in lung, gastrointestinal (including colorectal), and uterine cancers. The association held after adjusting for smoking, BMI, lifestyle, telomere length, and genetic risk scores for both aging and cancer, which is the part that makes it more than a restatement of "unhealthy people get cancer." They then went one layer deeper with the proteomic organ-specific clocks and found specific pairings: an older immune system tracked with early-onset lung cancer, and older adipose tissue tracked with early-onset colorectal cancer.

The honest limits matter here. This is observational, so accelerated aging is associated with cancer but not proven to cause it, and residual confounding is always possible. The organ-specific part is the most tentative: it used a smaller subgroup, few cancer cases, and the organ clocks were originally built in an overlapping UK Biobank sample, which the authors flag as a circularity risk they reduced but could not fully remove. The US replication had only about 100 cancer cases over short follow-up. And these are relative risks layered on a still-uncommon outcome, so a larger age gap is a population signal, not a personal diagnosis.

What you can follow

The deeper question is whether the age gap is a cause you can act on or just a sensitive thermometer for accumulated exposure. Answering it needs within-person tracking over time rather than one snapshot, since the authors' own data showed a person's PhenoAge tertile was only moderately stable across about four years. Also worth watching: the generational drift itself, which points at shared exposures (earlier obesity and metabolic dysfunction, diet, sedentary time, environmental chemicals, circadian disruption) rather than genetics, and the organ-specific leads, since immune-to-lung and adipose-to-colorectal give mechanistic hooks that future work can test directly.

Are there tests available today to measure this?

This is the unusually accessible part. PhenoAge runs on nine standard analytes you can get from routine bloodwork (albumin, alkaline phosphatase, creatinine, C-reactive protein, glucose, mean cell volume, red cell distribution width, white blood cell count, and lymphocyte percentage) plus your age, so if you have a recent CBC, a metabolic panel, and a CRP, you already have the inputs, and free PhenoAge calculators exist. The Klemera-Doubal clock is similar. The metabolomic clock relies on Nightingale-style NMR panels, which a few consumer services now offer. The organ-specific proteomic clocks are still research-grade and run on the Olink platform, not something you can order off the shelf yet. If anyone has computed their own PhenoAge from standard labs or used a consumer metabolomic-age product, it would be useful to compare notes on how reproducible the numbers were between draws, since stability is the weak point.

What you can track

The neat thing about PhenoAge is that its inputs are themselves modifiable health markers, so the levers and the readout overlap. C-reactive protein reflects inflammation, fasting glucose reflects metabolic health, and the rest move with the usual factors: not smoking, body composition, activity, and alcohol. Track those directly, and if you compute a biological age, treat it as a trend line across several measurements rather than a single verdict. A one-off elevated age gap is a prompt to look at the underlying labs, not a reason to assume anything about cancer risk in particular.

Paper: https://doi.org/10.1038/s41591-026-04448-w

High-sensitivity cardiac troponin T (hs-cTnT) and NT-proBNP are both blood markers of a heart under strain, and both are already standard orderable labs. Troponin leaks out when heart muscle cells are injured, NT-proBNP rises when the heart's walls are stretched. The question this study asked is a prevention question, not an emergency one: in people who do not yet have heart failure, do these markers forecast who will develop it, and do they add anything beyond ordinary risk factors like age, blood pressure, and diabetes.

The authors pooled individual data from 9 prospective cohorts, 41,427 people free of heart failure at the start, deliberately including people with chronic kidney disease and existing atherosclerotic disease since those groups usually get excluded. Over an average of about 11 years, 4,599 developed heart failure. Both biomarkers tracked with risk: each doubling of NT-proBNP carried a hazard ratio around 1.47, and each doubling of hs-cTnT around 1.41, so on their own both look impressive. The interesting part is what happened to actual predictive discrimination when each was added on top of a standard clinical risk model. NT-proBNP improved the C-statistic by about 0.030, a real bump. Hs-cTnT improved it by only about 0.008. And once NT-proBNP was already in the model, adding hs-cTnT moved discrimination by roughly 0.002, which is essentially nothing. NT-proBNP also held its predictive value in people with kidney disease and established cardiovascular disease, settings where biomarker interpretation often gets muddy.

Worth being clear on the limits. C-statistic gains always look small because it is hard to improve on a decent clinical model, and a hazard ratio of 1.4 per doubling is still meaningful for sorting individuals. This is also observational, so these are markers of risk, not proof that driving them down prevents heart failure. And none of this demotes troponin generally. It remains the backbone of diagnosing an actual heart attack. The narrow finding here is that for forecasting future heart failure in a person without symptoms, NT-proBNP is the more useful single test and troponin mostly rides along with it.

What you can follow

The practical thread is which biomarker to reach for and when. For heart failure risk and early staging, NT-proBNP is increasingly the workhorse, and recent cardiology guidance has leaned toward using it to identify people in the pre-symptomatic stages of heart failure who might benefit from earlier prevention. Hs-troponin earns its keep more in acute chest pain and heart attack rule-out. One technical detail worth knowing for any discussion: troponin assays are not interchangeable across manufacturers (the Roche hs-cTnT and the Abbott hs-cTnI run on different scales), so a number only means something next to its own reference range. Worth watching whether prevention trials using SGLT2 inhibitors and other therapies in people flagged by high NT-proBNP actually translate the prediction into fewer events.

Are there tests available today to measure this?

Yes, and this is the rare case where the answer is unambiguously available. NT-proBNP (or BNP) is a routine outpatient cardiology lab, and high-sensitivity troponin is widely run, though usually ordered in acute settings rather than as a screening test. Both can be drawn at rest in a clinic. Two caveats before anyone reads too much into a single value: both markers climb with age and with reduced kidney function, so they have to be interpreted alongside eGFR, and troponin in particular is not designed as a standalone wellness screen. If you have had an outpatient NT-proBNP or a resting hs-troponin drawn, it would be useful to hear how your clinician framed the result, since context is doing a lot of work with these numbers.

What you can track

The upstream, modifiable drivers of heart failure risk are the high-yield targets here, and they are all measurable: blood pressure, glycemic control (HbA1c), body weight and composition, and alcohol intake. Cardiorespiratory fitness belongs on that list too, since more time in moderate-to-vigorous activity has been linked to lower hs-troponin in midlife, which is a nice example of a lifestyle input nudging one of these markers. If you and your clinician do track NT-proBNP, the trend across several measurements tells you more than any single reading, and a one-off mildly elevated value is a reason to ask questions, not to panic.

Paper: https://doi.org/10.1161/JAHA.125.041683

Amino acids are about as basic as biochemistry gets, they are cheap to measure, and standard labs already quantify them. So the premise here is appealing: can the levels of a handful of amino acids in your blood tell you how well you are aging, without the cost of a methylation array or a thousand-protein panel.

The team built a model called AmiAge, a random forest trained on the concentrations of 18 amino acids in people ranging from 1 to 89 years old. The training set was large and varied, pulling from 9 studies, more than 11,000 in-house samples and over 270,000 publicly available ones across different demographic and genetic backgrounds, which is a real strength since a lot of clocks overfit to one cohort. The gap between AmiAge and actual chronological age (the "AmiAge Gap") lined up with established aging biomarkers and with disease risk. People with a larger gap showed more frailty, shorter telomeres, and higher rates of age-related disease. They then stripped the model down to just 8 amino acids (alanine, glutamine, glycine, histidine, leucine, phenylalanine, tyrosine, and valine) and it still held up, which is the part that makes it potentially practical.

The honest limits: most of these associations are cross-sectional, so a higher gap is linked to worse aging markers but this does not prove the amino acids are driving anything. Amino acid levels are also state-sensitive in a way methylation is not. They shift with your last meal, your protein intake, fasting, and recent exercise, so standardizing the blood draw matters a lot. A predictor that correlates with outcomes is not yet something you can move and expect benefit.

What you can follow

The interesting tension is cost versus stability. Amino-acid clocks could be far cheaper and more accessible than methylation or proteomic clocks, but they may also be noisier and more sensitive to short-term conditions, so the open question is how reproducible the AmiAge Gap is on repeat testing of the same person. A few of these amino acids are not random picks: the branched-chain ones (leucine, valine) and the aromatic ones (phenylalanine, tyrosine) repeatedly show up in metabolic dysfunction and insulin resistance, and glycine tends to run low in the same setting. Worth watching whether the gap mostly reflects metabolic health rather than aging per se, whether it replicates across different measurement platforms, and whether anything that lowers it actually changes hard outcomes.

Are there tests available today to measure this?

Partly, and this one is closer to reachable than most. A plasma amino acid profile is a real, orderable clinical test, often used in metabolic and genetic workups, and all 8 of the amino acids in the slimmed-down model are standard analytes on those panels. What is not available is the AmiAge algorithm itself as a packaged consumer product, so today you could in principle get the inputs but not an off-the-shelf score. If anyone has run a quantitative plasma amino acid panel and wants to share what was measured and how consistent repeat values were, that would be genuinely useful, since reproducibility is the whole question with a state-sensitive marker like this.

What you can track

Because several of these amino acids move with metabolic health, the trackable proxies today are the usual metabolic markers: fasting glucose, HbA1c, and fasting insulin or HOMA-IR if you can get them, alongside body composition and protein intake. If you ever do test amino acids directly, standardize the conditions hard (same fasting window, same time of day) and look at the trend across several draws rather than reading into one, because a single post-meal sample can move these numbers more than years of aging would.

Paper: https://doi.org/10.1038/s41467-026-73371-y

https://preview.redd.it/9nxmkrskc39h1.png?width=2905&format=png&auto=webp&s=91dd17ea737685fd92a0203661716355b883b5a4

Senescent cells are cells that have stopped dividing but refuse to die, and they leak a mix of inflammatory proteins into the blood. The problem has always been measuring them. You cannot easily biopsy every tissue, so the question here was whether the proteins these cells shed into circulation carry a useful signal.

The team started from a reference catalog of senescence proteins covering 14 distinct human cell types, then measured the corresponding proteins in plasma from two of the better aging cohorts we have: the Baltimore Longitudinal Study of Aging (1,275 people) and the InCHIANTI study in Italy (997 people). Two results stand out. First, the pooled senescence proteins predicted clinical traits like age and hypertension better than non-senescence proteins did, so the signal was not just generic noise. Second, and more interesting, a given cell type's senescence signature tended to map most strongly onto the health domain you would expect it to, which suggests these signatures carry some tissue specificity rather than all collapsing into one "inflammation" axis. The immune cell senescence signature in particular was associated with mortality and with disease that had not yet appeared at the time of the blood draw.

The honest limits: this is observational, the signatures are derived from a catalog rather than validated cell by cell in each person, and a protein in plasma is an indirect proxy for what is actually happening in a tissue. A signal that predicts outcomes is not yet a clock you can act on.

What you can follow

The live question in this corner of geroscience is whether circulating senescence markers are a readout you can move, or just a passive thermometer. The cleaner test will come from senolytic trials, where the whole point is to clear senescent cells, and where these kinds of signatures could serve as a pharmacodynamic marker. Worth watching: whether the immune senescence signature turns out to be causal or merely a marker of something upstream, and whether these signatures replicate on different proteomic platforms, since both cohorts lean on large-panel affinity proteomics.

Are there tests available today to measure this?

Not in any packaged, validated form that I'm aware of. There is no consumer "senescence panel" that reproduces these 14 cell-type signatures, and the classic tissue senescence marker p16 is not something you measure cleanly from a blood draw. Some individual proteins associated with senescence and inflammaging (GDF15, IL-6, and similar) can be ordered through standard labs, but that is a long way from what this paper actually built. If anyone has seen a research-use or clinical assay attempting a circulating senescence score, post it, because this is exactly the kind of thing that tends to get commercialized ahead of the evidence.

What you can track

Since the immune and inflammatory axis is doing a lot of the work here, the trackable proxies today are the ordinary inflammation markers: hs-CRP, and IL-6 if you can get it. Those are measurable, they move with lifestyle factors like fitness, sleep, and body composition, and they sit conceptually upstream of the immune senescence signal this study tied to mortality. As always, watch the trend over several measurements rather than reading anything into a single value.

Paper: https://doi.org/10.1016/j.celrep.2026.117389

This community is run by working scientists in the precision health space, and it exists for one reason: to talk seriously about the molecular and digital signals we can now measure in the human body. That means proteomics, metabolomics, epigenetics and methylation, biomarkers, aging clocks, wearables, and where all of it is heading. The field moves fast, some of it is genuinely exciting, and a fair amount is oversold. Our job here is to help tell those apart.

The rule of thumb is simple. Evidence-based discussion is welcome. Hype is not. If a claim rests on a press release, a podcast clip, or a supplement label, expect someone to ask for the paper. That is a feature, not hostility, and it applies to us too.

How the regular study posts are structured

Most days you will see a post built around a recent study. Every one follows the same five-part format so you can skim or go deep depending on your time:

1. Title. A plain-language statement of the actual finding, with sample size and population when it matters. No "this changes everything."

2. What the study found. A short summary of the result, and just as importantly, what it does not show.

3. What you can follow. Where this single paper sits in the wider research thread, so one result is treated as a data point and not the final word.

4. Are there tests available today? The most common question is "can I measure this in myself right now." Sometimes yes, often it is research-grade only, and when we are not sure, we say so and ask you.

5. What you can track. The grounded, measurable, usually modifiable inputs sitting underneath the headline biomarker, so the takeaway is practical instead of abstract.

Every post links the original paper at the bottom. Read it. Disagree with our reading of it. That is the point.

This is a collaboration, not a lecture

We bring scientific training, but no one here has the whole picture, and the most useful threads usually come from the comments. If you work in the field, run a relevant company, or sell something in the space, just disclose it when it is relevant and you are welcome. If you have used a test we are discussing, your real experience beats any marketing page. If you spot an error in our read of a paper, correct it, including when the mistake is ours.

The format above is a starting point, not scripture. If a section is not useful, or you want something we are not giving you, tell us and we will change it. Beginners welcome, skeptics especially welcome. Share comments and tell us what you are most curious about measuring.

This is incredible, what do the experts here think:

• No Ceiling for Improvement: Significant gains in brain health were observed across the board. Even top-tier performers continued to improve over 1,000 days, suggesting there is no known limit to brain optimization.
• The Low-Starter Advantage: Participants who entered the study with the lowest baseline scores demonstrated the most significant rates of improvement, demonstrating that poor brain health is not a life sentence.
• Small Habit Changes Make a Big Difference: Gains were directly correlated with consistency of utilization. Participants who engaged the most in 5 to 15 minutes of daily micro-training and adopted brain-healthy habits in their everyday lives achieved the highest brain health scores.
• Universal Potential at any Age: Younger adults saw gains equal to those in their 70s and 80s, debunking the myth that proactive brain health is only for seniors.

https://www.nature.com/articles/s41598-026-51403-3

https://www.science.org/doi/10.1126/science.adz1187